Related Experiment Video

Updated: May 22, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Is targeting of CD47-SIRPα enough for treating hematopoietic malignancy?

Xi Wen Zhao, Taco W Kuijpers, Timo K van den Berg

    Blood
    |May 5, 2012
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
    08:13

    Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

    Published on: December 3, 2020

    Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
    11:37

    Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

    Published on: June 18, 2018

    Related Experiment Videos

    Last Updated: May 22, 2026

    A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
    08:46

    A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

    Published on: November 12, 2019

    Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
    08:13

    Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

    Published on: December 3, 2020

    Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
    11:37

    Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

    Published on: June 18, 2018

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Regulation of Hematopoietic Stem Cells01:01

    Regulation of Hematopoietic Stem Cells

    All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Second-tier genetics improves newborn screening accuracy for SCID and other T cell deficiencies.

    Journal of human immunity·2026

    Identification of immunosuppressive neutrophils using multi-omics: why functional testing remains key.

    Frontiers in immunology·2026

    Managing non-SCID T cell lymphopenia after TREC-based newborn screening.

    Journal of human immunity·2026

    Kawasaki disease complicated by macrophage activation syndrome treated with canakinumab.

    Journal of human immunity·2026

    Heterogeneous Activated B Cell Compartments Arising Early and Transiently After SARS-CoV-2 Vaccination.

    European journal of immunology·2026

    Combining Activation-Induced Markers With PD-L1 Selectively Enhances Detection of Antigen-Specific T Cells in Virus-Infected Individuals.

    Journal of immunology research·2026

    CAR transgenic T-cell lymphoproliferative neoplasm (CTTLN): malignant transformation of cellular immunotherapy.

    Blood·2026

    MAP3K14 (NIK) synonymous variants drive altered splicing to activate NF-κB in mature B-cell malignancies.

    Blood·2026

    Vasculopathy in the Forecast: Biophysically Altered Red Cells Act as Hemodynamic Hail to Trigger Endothelial Dysfunction.

    Blood·2026

    Nipocalimab for warm autoimmune hemolytic anemia: results from the phase 2/3 randomized, double-blind ENERGY study.

    Blood·2026

    Inhibition of nucleoporin 214 depletes leukemia stem cells by promoting heme catabolism and lipid peroxidation.

    Blood·2026

    International Consensus Criteria for the Diagnosis, Treatment Initiation, and Response Assessment for T-LGL Leukemia.

    Blood·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us